Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivityEmmanuelle Moraes Ribeiro, Kathy-Ann Secker, Ana-Maria Nitulescu, Rebekka Schairer, Hildegard Keppeler, Anton Wesle, Hannes Schmid, Anita Schmitt, Brigitte Neuber, Daniela Chmiest, Silvia Podavini, Melanie Märklin, Boris Klimovich, Michael Schmitt, Fulya KorkmazSee the full list of authors
31 January 2024
Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapyNatalie K. Horvat, Isaac Karpovsky, Maggie Phillips, Megan M. Wyatt, Margaret A. Hall, Cameron J. Herting, Jacklyn Hammons, Zaid Mahdi, Richard A. Moffitt, Chrystal M. Paulos, Gregory B. Lesinski
8 January 2024
Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantationChao Ma, Peng Chen, Jishan Du, Lu Wang, Ning Lu, Jiaojun Sun, Xu Qilong, Yu Wang, Liping Dou, Dai-Hong Liu
6 January 2024
Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemiaShifaa M. Abdin, Daniela Paasch, Arnold Kloos, Marco Carvalho Oliveira, Mi-Sun Jang, Mania Ackermann, Andriana Stamopoulou, Philipp J Mroch, Christine S Falk, Constantin S von Kaisenberg, Axel Schambach, Michael Heuser, Thomas Moritz, Gesine Hansen, Michael MorganSee the full list of authors
22 December 2023
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicityDavid Bassan, Leehee Weinberger, Jason Yi, Tanya Kim, Michael R Weist, Gregor B Adams, Orit Foord, Neta Chaim, Sarit Tabak, Nir Bujanover, Yael Lopesco, Kristina Vucci, Caitlin Schnair, Limor Levy-Knafo, Richard L KendallSee the full list of authors
14 December 2023
Discovery of U2AF1 neoantigens in myeloid neoplasmsMelinda Ann Biernacki, Jessica Lok, Ralph Graeme Black, Kimberly A Foster, Carrie Cummings, Kyle B Woodward, Tim Monahan, Vivian G Oehler, Derek L Stirewalt, David Wu, Anthony Rongvaux, Hans Joachim Deeg, Marie Bleakley
12 December 2023
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodiesMd Faqrul Hasan, Amanda R Campbell, Tayler J Croom-Perez, Jeremiah L Oyer, Thomas A Dieffenthaller, Liza D Robles-Carrillo, Catherine A Cash, Jonathan E Eloriaga, Sanjana Kumar, Brendan W Andersen, Meisam Naeimi Kararoudi, Brian P Tullius, Dean A Lee, Alicja J Copik
11 December 2023
Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustionAlexandra Rose Teagle, Patricia Castro-Sanchez, Rebecca J Brownlie, Nicola Logan, Simran S Kapoor, David Wright, Robert J Salmond, Rose Zamoyska
6 December 2023
Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancerElisa C Toffoli, Amanda A van Vliet, Henk W M Verheul, Hans J van der Vliet, Jurriaan Tuynman, Jan Spanholtz, Tanja D de Gruijl
6 December 2023
iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targetingKristin M Snyder, Kate J Dixon, Zachary Davis, Martin Hosking, Geoffrey Hart, Melissa Khaw, Anders Matson, Ryan Bjordahl, Bryan Hancock, Soheila Shirinbak, Jeffrey S Miller, Bahram Valamehr, Jianming Wu, Bruce Walcheck
6 December 2023